retatrutide type 2 diabetes phase 2 trial results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Phase III retatrutide study demonstrates
Pay in 4 interest-free payments of $6.71 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25



00092-0/asset/cd1a18b7-2b41-4f1d-86f7-849737f41a90/main.assets/gr2.jpg)






















